Evidence map›Paper›PMID 38405213›Full record

ArticleContemporary oncology (Poznan, Poland)2023

Defining the mutational profile of lower-risk myelodysplastic neoplasm patients with respect to disease progression using next-generation sequencing and pyrosequencing.

Monika Adamska, Ewelina Kowal-Wiśniewska, Joanna Czerwińska-Rybak, Katarzyna Kiwerska, Marta Barańska, Weronika Gronowska, Jagoda Loba, Katarzyna Brzeźniakiewicz-Janus, Ewa Wasilewska, Aleksandra Łanocha and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary oncology (Poznan, Poland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Monika AdamskaDepartment of Haematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, Poznań, Poland.
Ewelina Kowal-WiśniewskaDepartment of Haematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, Poznań, Poland.
Joanna Czerwińska-RybakDepartment of Haematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, Poznań, Poland.
Katarzyna KiwerskaInstitute of Human Genetics, Polish Academy of Sciences, Poznań, Poland.
Marta BarańskaDoctoral School, Poznań University of Medical Sciences, Poznań, Poland.
Weronika GronowskaStudent Scientific Society, Poznań University of Medical Sciences, Poznań, Poland.
Jagoda LobaStudent Scientific Society, Poznań University of Medical Sciences, Poznań, Poland.
Katarzyna Brzeźniakiewicz-JanusDepartment of Haematology, Oncology, and Radiotherapy, University of Zielona Góra, Multi-specialist Hospital Gorzów Wielkopolski, Poland.
Ewa WasilewskaDepartment of Haematology, Medical University of Białystok, Białystok, Poland.
Aleksandra ŁanochaDepartment of Haematology with Bone Marrow Transplantation Unit, University Hospital No. 1 of Pomeranian Medical University, Szczecin, Poland.
Małgorzata Jarmuż-SzymczakDepartment of Haematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, Poznań, Poland.
Lidia GilDepartment of Haematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, Poznań, Poland.
Poznan University of Medical Sciences · PLInstitute of Human Genetics · PLMedical University of Silesia · PLPomeranian Medical University · PLUniversity of Zielona Góra · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Lower-risk myelodysplastic neoplasms (LR-MDS) comprise the majority of MDS. Despite favourable prognoses, some patients remain at risk of rapid progression. We aimed to define the mutational profile of LR-MDS using next-generation sequencing (NGS), Sanger Sequencing (SSeq), and pyrosequencing. Material and methods: Samples from 5 primary LR-MDS (67 exons of Results: Next-generation sequencing results identified 13 DNA sequence variants in 7 genes, comprising 8 mutations in 6 genes ( Conclusions: We suggest using NGS to determine the LR-MDS mutational profile at diagnosis and suspicion of disease progression. Moreover, PB and SAL molecular testing represent useful tools for monitoring LR-MDS at higher risk of progression. However, the results need to be confirmed in a larger group.

Indexed as

acute myeloid leukaemia myelodysplasia-relatedallogenic hematopoietic cell transplantationlower-risk myelodysplastic neoplasmsNGSpyrosequencing

Identifiers

PMID38405213
PMCPMC10883195
OpenAlexW4392011294

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.